NDC product
Fosaprepitant
NDC 0338-0008 · Baxter Healthcare Corporation
Key facts
| Product NDC | 0338-0008 |
|---|---|
| Proprietary name | Fosaprepitant |
| Nonproprietary name | Fosaprepitant Dimeglumine |
| Substances | FOSAPREPITANT DIMEGLUMINE |
| Dosage form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRAVENOUS |
| Labeler | Baxter Healthcare Corporation |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA211860 |
| Pharmacologic classes | Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Neurokinin 1 Antagonists [MoA], Substance P/Neurokinin-1 Receptor Antagonist [EPC] |
| Marketing start | Sep 5, 2019 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: